These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32108878)

  • 1. Efficacy of piperacillin in combination with novel β-lactamase inhibitor IID572 against β-lactamase-producing strains of Enterobacteriaceae and Staphylococcus aureus in murine neutropenic thigh infection models.
    Growcott EJ; Gamboa L; Roth T; Lopez S; Osborne CS
    J Antimicrob Chemother; 2020 Jun; 75(6):1530-1536. PubMed ID: 32108878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of the novel monobactam LYS228 in a neutropenic murine thigh model of infection.
    Growcott EJ; Cariaga TA; Morris L; Zang X; Lopez S; Ansaldi DA; Gold J; Gamboa L; Roth T; Simmons RL; Osborne CS
    J Antimicrob Chemother; 2019 Jan; 74(1):108-116. PubMed ID: 30325447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model.
    Gill CM; Abdelraouf K; Nicolau DP
    J Antimicrob Chemother; 2021 Mar; 76(4):993-1000. PubMed ID: 33438033
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Lasko MJ; Abdelraouf K; Nicolau DP
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33431414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.
    Craig WA; Andes DR
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1577-82. PubMed ID: 23274659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel framework to compare the effectiveness of β-lactamase inhibitors against extended-spectrum β-lactamase-producing Enterobacteriaceae.
    Abodakpi H; Chang KT; Zhou J; Byerly C; Tam VH
    Clin Microbiol Infect; 2019 Sep; 25(9):1154.e9-1154.e14. PubMed ID: 30664934
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Abdelraouf K; Stainton SM; Nicolau DP
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant.
    Mentec H; Vallois JM; Bure A; Saleh-Mghir A; Jehl F; Carbon C
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1883-9. PubMed ID: 1329634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations.
    Bonfiglio G; Livermore DM
    J Antimicrob Chemother; 1993 Sep; 32(3):431-44. PubMed ID: 8262865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of the in vitro activity of piperacillin/tazobactam.
    Daley D; Mulgrave L; Munro R; Neville S; Smith H; Dimech W
    Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.
    Wiskirchen DE; Crandon JL; Furtado GH; Williams G; Nicolau DP
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3220-5. PubMed ID: 21518838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.
    Peterson LR
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():181-4. PubMed ID: 18154544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria.
    Chang SC; Hsu LY; Luh KT; Hsieh WC
    J Formos Med Assoc; 1991 Oct; 90(10):947-52. PubMed ID: 1685175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
    Nicasio AM; VanScoy BD; Mendes RE; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
    Fass RJ; Prior RB
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing
    Abodakpi H; Chang KT; Gao S; Sánchez-Díaz AM; Cantón R; Tam VH
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IID572: A New Potentially Best-In-Class β-Lactamase Inhibitor.
    Reck F; Bermingham A; Blais J; Casarez A; Colvin R; Dean CR; Furegati M; Gamboa L; Growcott E; Li C; Lopez S; Metzger L; Nocito S; Ossola F; Phizackerley K; Rasper D; Shaul J; Shen X; Simmons RL; Tang D; Tashiro K; Yue Q
    ACS Infect Dis; 2019 Jul; 5(7):1045-1051. PubMed ID: 30861342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of human-simulated exposures of meropenem/vaborbactam and meropenem against OXA-48 β-lactamase-producing Enterobacterales in the neutropenic murine thigh infection model.
    Gill CM; Asempa TE; Nicolau DP
    J Antimicrob Chemother; 2021 Jan; 76(1):184-188. PubMed ID: 33103202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.